A new wave of device code phishing shows how threat actors are scaling account compromise using AI and end‑to‑end automation.
Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results